Matsumoto K, Takahashi M, Sato K, et al. A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med. 2020;9:3319--3327. 10.1002/cam4.2979

This study is registered with University Hospital Medical Information Network in Japan: Registry number is UMIN000008897.

1. INTRODUCTION {#cam42979-sec-0005}
===============

Breast cancer is the most common type of cancer affecting women in Japan. Its standard perioperative chemotherapy regimen comprises a combination of anthracycline and cyclophosphamide regimen (AC‐based regimen) such as doxorubicin + cyclophosphamide (AC), epirubicin + cyclophosphamide (EC), or 5‐fluorouracil (5FU) + AC (FAC) or EC (FEC). All these combinations are associated with a high risk of chemotherapy‐induced nausea and vomiting (CINV), the most common adverse event for patients with breast cancer.

The use of effective antiemetics, such as steroids, serotonin receptor antagonists (5‐HT3 RAs), and neurokinin 1 (NK‐1) inhibitors (NK‐1 RAs), drastically improves CINV. In this regard, a three‐drug combination has been recommended for patients with breast cancer who are receiving AC‐based regimen on the basis of three major clinical guidelines: the American Society of Clinical Oncology (ASCO) guidelines,[1](#cam42979-bib-0001){ref-type="ref"} the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology,[2](#cam42979-bib-0002){ref-type="ref"} and the Multinational Association of Supportive Care in Cancer (MASCC).[3](#cam42979-bib-0003){ref-type="ref"}

Palonosetron, a second‐generation 5‐HT3 RA, has a longer half‐life than other first‐generation 5‐HT3 RAs. The PROTECT trial was the first trial that compared palonosetron to granisetron combined with dexamethasone for patients receiving highly emetogenic chemotherapy (HEC) such as cisplatin (CDDP) or AC‐based regimen. In that trial, palonosetron was better than granisetron as the primary endpoint, which is complete response (CR: no vomiting and no rescue usage) in delayed phase (\>24‐120 hours (h) after the chemotherapy) for patients receiving CDDP or AC‐based regimen combined with dexamethasone.[4](#cam42979-bib-0004){ref-type="ref"} In subgroup analysis for patients receiving AC‐based regimen, the CR during delayed phase and the CR during acute phase (0‐24 hours post chemotherapy) was 50% vs 61.1% and 64.8% vs 69% in granisetron and palonosetron, respectively. One limitation of the PROTECT study is that it did not use NK‐1 RAs. A systematic review and meta‐analysis revealed that palonosetron is better than first‐generation 5‐HT3 RAs, although none of the eight trials included in the meta‐analysis used NK‐1 RAs.[5](#cam42979-bib-0005){ref-type="ref"} Therefore, it remains unknown whether palonosetron is better than first‐generation 5‐HT3 RAs when combined with both dexamethasone and NK‐1 RAs as stated in the ASCO guidelines.[6](#cam42979-bib-0006){ref-type="ref"}

Fosaprepitant dimeglumine (Fos), a water‐soluble, phosphorylated analog of aprepitant, is rapidly converted to aprepitant after intravenous (IV) administration. The EASE study showed that a triple‐antiemetic regimen containing a single dose of IV Fos is noninferior to a triple‐antiemetic regimen with 3 days of oral administration of aprepitant.[7](#cam42979-bib-0007){ref-type="ref"}

This study seeks to investigate whether a three‐drug combination of palonosetron with dexamethasone and Fos is better than granisetron + dexamethasone + Fos in preventing CINV in patients with breast cancer receiving AC‐based regimen.

2. PATIENTS AND METHODS {#cam42979-sec-0006}
=======================

2.1. Study design and treatment {#cam42979-sec-0007}
-------------------------------

The West Japan Oncology Group (WJOG) 6811B study (UMIN000008897) is a double‐blind, active‐controlled, multicenter phase 3 trial that evaluates the efficacy and safety of palonosetron or granisetron combined with dexamethasone and Fos for chemo‐naive patients with breast cancer receiving AC‐based regimen in cycle one. Patients were randomly assigned to palonosetron or granisetron treatment groups after stratification using minimization method. Stratification factors included institution, age (\<55 years or ≥55 years), and the chemotherapy regimen (AC/EC/FAC/FEC). After stratification, the patients were randomly assigned to palonosetron or granisetron treatment. It was ensured that treatment assignments were made by personnel that were not involved in the study at each institution. The dose of the administered palonosetron was 0.75 mg, not 0.25 mg. This dose is the approved dose in Japan based on randomized studies previously conducted in Japan.[8](#cam42979-bib-0008){ref-type="ref"}, [9](#cam42979-bib-0009){ref-type="ref"} A subsequent systematic review reported that the doses of 0.25 and 0.75 mg achieved same therapeutic efficacy.[5](#cam42979-bib-0005){ref-type="ref"} The dose of administered granisetron in the study was 1 mg.

The inclusion and exclusion criteria for the study were as follows: women aged ≥20 years with invasive breast cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0‐2, adequate organ function, and no history of chemotherapy. Antiemetic medication in the past 72 hours before enrollment was not allowed. All patients received dexamethasone (12 mg on day 1, 8 mg on day 2 and 3) and Fos 150 mg at day 1. To minimize phlebitis, Fos was diluted with ≥250 mL of normal saline and infused for ≥30 min.

The study protocol was approved by the institutional review board of each institution. All participants provided written informed consent before participating in the study.

2.2. Assessments {#cam42979-sec-0008}
----------------

The primary endpoint was the complete response (CR) rate of emesis in the delayed phase and was defined as the percentage of patients without vomiting or rescue drug usage for emesis during \>24‐120 hours after chemotherapy. Secondary endpoints were the CR rate of emesis in the acute phase, the CR rate of emesis in the overall phase (0‐120 hours after chemotherapy); the CR rates of nausea or vomiting during acute, delayed, and overall phases; patient‐reported outcomes (PRO); and safety (using Common Terminology Criteria for Adverse Events \[CTCAE\] ver. 4). Treating physicians answered the causality of each adverse events (multiple choice allowed). Severe adverse events (SAEs) were defined as adverse events related to hospitalization, prolongation of hospitalization, or death. All patients were asked to maintain a diary to report episodes of nausea, usage of rescue drugs, vomiting, adverse events, and PROs. PROs include two questions regarding the frequency and severity of nausea.

2.3. Statistical analyses {#cam42979-sec-0009}
-------------------------

On the basis of previous studies,[10](#cam42979-bib-0010){ref-type="ref"}, [11](#cam42979-bib-0011){ref-type="ref"}, [12](#cam42979-bib-0012){ref-type="ref"}, [13](#cam42979-bib-0013){ref-type="ref"}, [14](#cam42979-bib-0014){ref-type="ref"} we expected a 65% CR during delayed phase in regimen A (granisetron) and an 80% CR during delayed phase in regimen B (palonosetron). To perform a chi‐square test with continuity correction at two‐sided significance level of .05 and a power of 0.80, we determined that 302 patients will be needed in the PPS. Assuming that 8% of the patients were ineligible or lost to follow‐up, we planned the study sample size as 330.

The proportion of the primary endpoint, the CR during delayed phase, was obtained for each regimen. Chi‐square test with the continuity correction, where the significance level was .05 (two‐sided) was used for comparison. We performed explanatory subgroup analyses of some background factors and multivariable logistic regression analysis with age, chemotherapy regimen, body mass index (BMI), drinking habit, motion sickness, and morning sickness as explanatory variables, in addition to the regimen. We performed similar analyses for the secondary endpoints.

3. RESULTS {#cam42979-sec-0010}
==========

3.1. Study conducts {#cam42979-sec-0011}
-------------------

From December 2012 to October 2014, 341 patients were randomized. Three patients were ineligible or withdrew their consent before the start of the treatment. The three were all removed from the FAS dataset. Four patients did not start the treatment protocol (delaying more than 2 weeks due to personal events or laboratory findings), two patients did not complete the treatment protocol (due to allergic reaction by anticancer agents), and six patients did not complete the protocol specified for the follow‐up. After adjusting for all these factors, the PPS dataset includes 326 patients. The CONSORT flaw is shown in Figure [1](#cam42979-fig-0001){ref-type="fig"}.

![CONSORT flow diagram. Abbreviations: FAS, full analysis set; GRA, granisetronnisetron; PAL, palonosetron; PPS, per‐protocol set; obs, observation](CAM4-9-3319-g001){#cam42979-fig-0001}

3.2. Patient characteristics {#cam42979-sec-0012}
----------------------------

The patient characteristics are summarized in Table [1](#cam42979-tbl-0001){ref-type="table"}.

###### 

Patient characteristics

                                            GRANISETRON n = 164   PALONOSETRON n* *= 162
  ----------------------------------------- --------------------- ------------------------
  Age (years), median (range)               54 (27‐82)            54 (30‐74)
  \<55, n (%)                               87 (53%)              83 (51.2%)
  ≥55, n (%)                                77 (47%)              79 (48.8%)
  Height (cm), median (range)               156 (139‐174)         156 (144‐167)
  Weight (kg), median (range)               54.5 (35.2‐91.8)      55.9 (36.3‐86.0)
  BMI (kg/m^2^), median (range)             22.2 (16.0‐36.7)      23.1 (15.8‐35.0)
  \<25, n (%)                               126 (76.8%)           113 (69.8%)
  ≥25, n (%)                                38 (23.2%)            49 (30.2%)
  ECOG performance status, n (%)                                  
  0                                         163 (99.4%)           161 (99.4%)
  1                                         1 (0.6%)              1 (0.6%)
  2                                         0 (0%)                0 (0%)
  Chemotherapy regimen, n (%)                                     
  AC                                        21 (12.8%)            19 (11.7%)
  EC                                        47 (28.7%)            49 (30.2%)
  FAC                                       0 (0.0%)              0 (0.0%)
  FEC                                       96 (58.5%)            94 (58.0%)
  History of drinking, n (%)                                      
  Yes                                       41 (25.0%)            50 (30.9%)
  No                                        121 (73.8%)           110 (67.9%)
  Unknown                                   2 (1.2%)              2 (1.2%)
  Motion sickness, n (%)                                          
  Yes                                       40 (24.4%)            42 (25.9%)
  No                                        117 (71.3%)           114 (70.4%)
  Unknown                                   7 (4.3%)              6 (3.7%)
  Morning sickness, or nulliparity, n (%)                         
  Yes                                       89 (54.3%)            81 (50.0%)
  No                                        51 (31.1%)            51 (31.5%)
  Nulliparity                               17 (10.4%)            25 (15.4%)
  Unknown                                   7 (4.3%)              5 (3.1%)
  Treatment setting, n (%)                                        
  Adjuvant                                  81 (49.4%)            92 (56.8%)
  Neoadjuvant                               83 (50.6%)            70 (43.2%)

Abbreviations: AC, doxorubicin + cyclophosphamide; BMI, body mass index; EC, epirubicin + cyclophosphamide; ECOG, Eastern Cooperative Oncology Group;FAC, 5‐fluorouracil + doxorubicin + cyclophosphamide; FEC, 5‐fluorouracil + epirubicin + cyclophosphamide; GRANISETRON, granisetron; PALONOSETRON, palonosetron.
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Almost half of the patients were young (\<55 years), with a quarter being overweight (BMI \> 25 kg/m^2^). In addition, 88% of the patients were on epirubicin, 30% had a drinking habit, 25% had motion sickness, and almost half had a history of morning sickness. These patient characteristics were well balanced between regimens A and B.

3.3. Fos infusion time {#cam42979-sec-0013}
----------------------

In this study, 83.7%, 6.7%, 2.1%, and 1.8% of patients received Fos for 30‐40, 40‐50, 60, and \>60 minutes, respectively.

3.4. Efficacy {#cam42979-sec-0014}
-------------

### 3.4.1. Primary endpoint and subgroup analysis {#cam42979-sec-0015}

For the primary endpoint, the CR during the delayed phase was 60.4% (99/164) vs 62.3% (101/162) in patients receiving regimen A and regimen B, respectively (*P* = .8). Although the CR rate in every 24‐hours period was better in regimen B (Figure [2A](#cam42979-fig-0002){ref-type="fig"}) than in regimen A, the CR during the overall phase was identical in both regimens \[54.9% (90/164) vs 54.9% (89/162) (*P* = 1.0)\].

![(A) Complete response in 120 hours after chemotherapy. Abbreviations: hrs, hours; A, granisetron; B, palonosetron. (B) Nausea control during each phase after chemotherapy. Abbreviations: Acute, 0‐24 hours after chemotherapy; Delay, \>24‐120 hours after chemotherapy: Overall, 0‐120 hours after chemotherapy](CAM4-9-3319-g002){#cam42979-fig-0002}

Multivariable logistic regression analysis (Table [2](#cam42979-tbl-0002){ref-type="table"}) revealed the following: First, a history of motion sickness was a statistically significant risk factor for the CR during acute phase (OR = 0.57; 95% CI 0.32‐1.01; *P* = .053), the CR during delayed phase (OR = 0.51; 95% CI 0.30‐0.88; *P* = .015), and the CR during overall phase (OR = 0.49; 95% CI 0.29‐0.84; *P* = .009).

###### 

Logistic regression analysis of predictive factors for CINV

             CR during delayed phase   CR during acute phase   CR during overall phase                           
  ---------- ------------------------- ----------------------- ------------------------- ------- ------- ------- -------
  Age        [\>]{.ul}55/\<            0.87                    0.585                     1.81    0.037   1.23    0.402
  Rx         AC/FEC                    0.3                     0.005                     0.48    0.107   0.32    0.008
  EC/FEC     1.05                      0.885                   0.81                      0.549   0.75    0.342   
  BMI        [\>]{.ul}25/\<            0.7                     0.189                     1.28    0.431   0.67    0.14
  Drinking   Yes/no                    0.77                    0.333                     0.88    0.653   0.75    0.273
  Motion     Yes/no                    0.51                    0.015                     0.57    0.053   0.49    0.009
  Morning    Yes/no                    0.69                    0.176                     0.71    0.271   0.68    0.153

Abbreviations: AC, doxorubicin + cyclophosphamide; BMI, body mass index; CINV, chemotherapy‐induced nausea and vomiting; drinking, drinking habit; EC, epirubicin + cyclophosphamide; FEC, 5‐fluorouracil + epirubicin + cyclophosphamide; morning, history of morning sickness; motion, history of motion sickness; OR, odds ratio; Rx, regimen.
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Second, AC as a regimen was also a statistically significant risk factor for the CR during delay phase (OR = 0.30; 95% CI 0.13‐0.70; *P* = .005) and the CR during overall phase (OR = 0.32; 95% CI 0.14‐0.74; *P* = .008). Third, age was a statistically significant risk factor only for the CR during acute phase (OR = 1.81; 95% CI 1.03‐3.16; *P* = .037). Considering these risk factors, none of the planned subgroup analyses showed significant differences between regimens A and B. The BMI, drinking habit, and morning sickness were not risk factors for the CR during acute, delayed, and overall phase.

### 3.4.2. Secondary endpoints {#cam42979-sec-0016}

The percentage of patients without vomiting during the acute, delayed, and overall phases after the administration of regimens A and B was 93.9% (154/164) vs 95.7% (155/162) (*P* = .636), 82.3% (135/164) vs 89.5% (145/162) (*P* = .088), and 79.9%(131/164) vs 85.8% (139/162) (*P* = .203), respectively. The percentage of patients without nausea during the acute, delayed, and overall phases after administration of regimens A and B was 45.1% (74/164) vs 51.2% (83/162) (*P* = .32), 28.0% (46/164) vs 40.1% (65/162) (*P* = .029), and 24.4% (40/164) vs 32.7% (53/162) (*P* = .123), respectively (Figure [2B](#cam42979-fig-0002){ref-type="fig"}). Regarding the PROs, the frequency of nausea was lower after the administration of regimen B compared to regimen A (*P* = .014).

### 3.4.3. Safety {#cam42979-sec-0017}

Three patients experienced SAEs during the study period: delirium after febrile neutropenia (regimen B), acute pancreatitis (regimen A), and febrile neutropenia (regimen B). None of the SAEs was considered to be related to the use of antiemetics. The nonhematologic toxicities are summarized in Table [3](#cam42979-tbl-0003){ref-type="table"}. Adverse events related to antiemetics include constipation, headache, and infusion site reaction (ISR). Regarding ISR, among 72 patients experiencing ISR (38 patients in regimen A and 34 patients in regimen B), the physicians judged 68 (94.4%) ISRs as related to chemotherapy and 40 (55.5%) ISRs as related to antiemetics (Fos). Most of these adverse events were grade 1 or 2. We observed no differences between regimens A and B.

###### 

Nonhematologic adverse events experienced by two or more patients

                 Granisetron (%)   Palonosetron (%)                                   
  -------------- ----------------- ------------------ ----- ------ ------ ----- ----- ------
  Nausea         47                9                  0.6   56.8   43     8     0     51.4
  Vomiting       10.8              2.4                0.6   13.7   10.8   1.2   0     11.9
  Constipation   26.9              0.6                0     27.5   31.7   2.4   0     34
  Headache       12                0                  0     12     13.2   0     0     13.2
  ISR            21.6              1.2                0.6   23.3   18     2.4   0     20.3
  FN             ---               ---                4.2   4.2    ---    ---   5.4   5.4

Abbreviations: FN, febrile neutropenia; G, grade; ISR, infusion site reaction.
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4. DISCUSSION {#cam42979-sec-0018}
=============

This study examined the administration of palonosetron or granisetron combined with dexamethasone and Fos for preventing CINV in breast cancer patients who placed on AC‐based regimen. This is the first randomized study to report the efficacy of Fos for patients with breast cancer receiving AC‐based regimen. Palonosetron was not found to be better than granisetron in terms of the CR during the delayed phase, acute phase, and the overall phase, although some secondary endpoints, including delayed nausea and patient‐reported frequency of emesis, were improved in patients who were administered palonosetron. Preplanned subgroup analysis revealed a history of motion sickness as a distinct risk factor; however, its presence or absence did not help predict the treatment effects of palonosetron.

A phase 3 trial (the TRIPLE study) compared the treatment effects of palonosetron and granisetron in combination with aprepitant and dexamethasone in patients receiving CDDP and showed that palonosetron is better than granisetron in terms of the CR during the delayed phase (67.2% vs 59.1%; *P* = .0142).[15](#cam42979-bib-0015){ref-type="ref"} Interestingly, the CR during the delayed phase in the granisetron regimen was similar in both TRIPLE (59.1%) and WJOG 6811B (60.4%) studies, whereas the CR during delayed phase in the palonosetron regimen was slightly different (67.2% in TRIPLE vs 62.3% in WJOG 6811B). Two reasons may explain the difference in the treatment effect of palonosetron between the TRIPLE and WJOG 6811B studies. First is the difference in the chemotherapy drug: CDDP in the TRIPLE study vs AC‐based regimen in the WJOG 6811B study. The CINV peak in AC‐based regimen tends to be later compared with the CDDP regimen,[16](#cam42979-bib-0016){ref-type="ref"} although in the PROTECT study, palonosetron improved CR during the delayed phase (from 50% to 61.1%) in AC/EC group, which was similar in the CDDP group (from 40.6% to 53.5%). Second is the patient background: 75% of patients in the TRIPLE study were males, whereas all patients in the WJOG 6811B study were females. Tamura et al conducted a nationwide registry study in Japan and concluded that sex remains a distinct risk factor for CINV, even among patients receiving NK‐1 RAs.[17](#cam42979-bib-0017){ref-type="ref"} The reason why palonosetron did not work as desired (combined palonosetron with 3‐days dexemathasone and NK1‐RA after AC‐based regimen) needs further study.

Navari et al reported the usefulness of olanzapine as the fourth drug with dexamethasone, 5‐HT‐3 RA, and NK‐1 RA. They found that olanzapine improves the CR during the delayed phase from 52% to 67% and no nausea during the delayed phase from 25.4% to 42.4%.[18](#cam42979-bib-0018){ref-type="ref"} The newest ASCO guideline recommends upfront olanzapine for all patients with breast cancer on the basis of this study,[19](#cam42979-bib-0019){ref-type="ref"} although MASCC/ESMO guidelines stated that olanzapine may be considered with a triple regimen, particularly when nausea is an issue.

Another issue related to safety was ISR, observed in one fifth of the patients in both arms of the study. This frequency is higher than the data (2.7%) reported in the EASE study.[7](#cam42979-bib-0007){ref-type="ref"} A recent study reported Fos administered in the peripheral vein with AC‐based regimen would lead to a higher risk of ISR.[20](#cam42979-bib-0020){ref-type="ref"} This study reproduced a similar result. The timing of ISRs onset may vary because half of the physicians reported ISRs to be related to Fos, whereas most of them also reported ISRs to be related to chemotherapy. Even if ISRs begin during chemotherapy infusion, the high frequency of ISR in this study strongly suggests Fos increases the risk. We do believe that a follow‐up study using Fos with AC‐based regimen should avoid dosing in the peripheral veins.

This study, however, has several limitations. First, dexamethasone was administered on days 1, 2, and 3, although the newest guidelines recommend single dose dexamethasone for patients receiving AC‐based regimen. This is also supported by a recent study[21](#cam42979-bib-0021){ref-type="ref"} that proved noninferiority of single dose dexamethasone as triplet regimen with palonosetron and aprepitant for patients receiving HEC (including AC‐based regimen). Omitting dexamethasone on day 2 and day 3 might affect the conclusion of this study. Second, the sample size was relatively small for a phase 3 study. However, the difference in the CR during the delayed phase was small (1.9%) and the CR during the overall phase was identical in regimens A and B; hence, a larger study might not necessarily lead to a clinically meaningful difference.

5. CONCLUSION {#cam42979-sec-0019}
=============

Palonosetron exerts efficacy against delayed CINV which is not better than that of the combination with granisetron for patients with breast cancer receiving 3 days dexamethasone and Fos after AC‐based regimen, even though palonosetron reduced significantly delayed nausea. Both palonosetron and granisetron combined with steroids and NK‐1 RAs are good options for CINV prevention in patients with breast cancer receiving AC‐based regimen. These patients are still at a higher risk for nausea, especially during the delayed phase. Administration of Fos in the peripheral vein with AC‐based regimen should be avoided because it leads to higher risk of ISR.
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